Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA

Genetic sequencing of malignancies has become increasingly important to uncover therapeutic targets and capture the tumor’s dynamic changes to drug sensitivity and resistance through genomic evolution. In lung cancers, the current standard of tissue biopsy at the time of diagnosis and progression is...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Oncology 2017-01, Vol.2017 (2017), p.1-5-004
Main Authors: Li, Bob T., Rudin, Charles M., Isbell, James M., Razavi, Pedram, Chabon, Jacob J., Offin, Michael, Diehn, Maximilian
Format: Article
Language:English
Subjects:
Biopsy
Blood
Cancer
Cancer therapies
Cloning
Deoxyribonucleic acid
Diagnosis
DNA
DNA sequencing
FDA approval
Genetic aspects
Genomes
Lung cancer
Metastasis
Methods
Mutation
Nucleotide sequencing
Plasma
Precision medicine
Review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Genetic sequencing of malignancies has become increasingly important to uncover therapeutic targets and capture the tumor’s dynamic changes to drug sensitivity and resistance through genomic evolution. In lung cancers, the current standard of tissue biopsy at the time of diagnosis and progression is not always feasible or practical and may underestimate intratumoral heterogeneity. Technological advances in genetic sequencing have enabled the use of circulating tumor DNA (ctDNA) analysis to obtain information on both targetable mutations and capturing real-time Darwinian evolution of tumor clones and drug resistance mechanisms under selective therapeutic pressure. The ability to analyze ctDNA from plasma, CSF, or urine enables a comprehensive view of cancers as systemic diseases and captures intratumoral heterogeneity. Here, we describe these recent advances in the setting of lung cancers and advocate for further research and the incorporation of ctDNA analysis in clinical trials of targeted therapies. By capturing genomic evolution in a noninvasive manner, liquid biopsy for ctDNA analysis could accelerate therapeutic discovery and deliver the next leap forward in precision medicine for patients with lung cancers and other solid tumors.
ISSN:1687-8450
1687-8450
DOI:10.1155/2017/4517834